A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel
详细信息 查看全文
- 作者：Xiaolong Jing ; Li Deng ; Baoan Gao ; Lin Xiao ; Yingying Zhang ; Xingfa Ke ; Jianhao Lian ; Qiang Zhao ; Lulu Ma ; Jianzhong Yao ; Jianming Chen
- 关键词：Lipid emulsion ; Drug carrier ; Poorly water-soluble drug ; Paclitaxel ; Tumor
- 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
- 出版年：February, 2014
- 年：2014
- 卷：10
- 期：2
- 页码：371-380
- 全文大小：1386 K
文摘
A novel polyethylene glycol 400 (PEG400) mediated lipid nanoemulsion as drug-delivery carrier for paclitaxel (PTX) was successfully developed. The formulation comprised a PEG400 solution of the drug (25 mg/mL) that would be mixed with commercially 20% lipid emulsion to form PTX-loaded nanoemulsion (1 mg/mL) prior to use. This two-vial formulation of PTX-loaded lipid nanoemulsion (TPLE) could significantly reduce extraction of reticuloendothelial system (RES) organs and increase tumor uptake, and exhibited more potent antitumor efficacy on bearing A2780 or Bcap-37 tumor nude mice compared to conventional PTX-loaded lipid nanoemulsion (CPLE). TPLE did not cause haematolysis and intravenous irritation response yet, and showed the same cytotoxicity against HeLa cells as Taxol庐, and its LD50 was 2.7-fold higher than that of Taxol庐, suggesting its good safety and druggability. In addition, TPLE displayed distinctly faster release of PTX, a greater proportion of PTX in phospholipids layer and a smaller share in oil phase than CPLE. From the Clinical Editor: This study demonstrates the feasibility and potential advantage of a novel PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in clinical application for the cancer therapy.
From the Clinical Editor
This team of investigators convincingly demonstrates the feasibility and potential advantage of a PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in cancer therapy, documenting superior safety and faster release of PTX compared to commercially available formulations.